News

Cosmos Health (COSM) – Balance Sheet Strengthens; Fourth Quarter Growth Catalysts in Focus

Health
0 min read


Thursday, November 19, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Richard Magnusen, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q3 revenue below preliminary results. Cosmos Health reported third-quarter revenue of $16.7 million, down 2.5% year over year and below its previously announced preliminary revenue of $17.4 million. Gross margin improved 465 basis points sequentially to 12.6%, while adjusted EBITDA was a loss of $0.9 million.

Higher-margin businesses remain the key growth drivers. The company’s U.S. direct-to-consumer business reached more than 12,500 active subscriptions as of October 31, representing approximately $1.83 million in monthly subscription value. Cana Laboratories’ contract manufacturing pipeline exceeded 32.7 million units, providing additional visibility into potential higher-margin revenue growth.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy